Tolerion reports Phase II data for Type I diabetes vaccine

Tolerion Inc. (Portola Valley, Calif.) said all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of

Read the full 213 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE